April 22, 2019
Lilly’s drug Taltz for nr-axSpA meets endpoints in Phase 3 testing, approval application expected this year
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.